{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:18:59Z","timestamp":1790871539539,"version":"4.1.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Irritable bowel syndrome (IBS) is a functional bowel disorder. Gut dysbiosis involves in pathogenesis of IBS. Limited studies compared efficacy of fecal microbiota transplantation (FMT) via different routes of administration. This study aimed to compare efficacy of encapsulated FMT, FMT via rectal enema, and placebo in IBS patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this double-blind, randomized, placebo-controlled study, we enrolled patients aged 18\u201370 years with IBS defined by Rome IV criteria at Thammasat university, Thailand. Patients were randomized into three groups: (1) encapsulated FMT (six capsules twice daily for two consecutive days, total 50 g of stool), (2) FMT via rectal enema (50 g of stool in 200 mL of isotonic saline), or (3) placebo. Primary endpoint was clinical response defined by \u226550-point decrease in IBS-symptom severity score (IBS-SSS) at 4 weeks. Secondary outcomes were quality of life and changes of fecal microbiota composition after treatment. The study was registered with <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>, number NCT06201182.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From August 20, 2020, to February 15, 2024, 45 patients were randomized to receive encapsulated FMT (<jats:italic>n<\/jats:italic> = 15), FMT via rectal enema (<jats:italic>n<\/jats:italic> = 15), or placebo (<jats:italic>n<\/jats:italic> = 15). There was no difference in patient characteristics and baseline IBS-SSS between groups. Encapsulated FMT provided significantly improved IBS-SSS (166.7 \u00b1 73.7 vs. 269.3 \u00b1 69.5, <jats:italic>p<\/jats:italic> = 0.001), clinical response (86.7 vs. 26.7%, <jats:italic>p<\/jats:italic> = 0.001), and quality of life (31.7 \u00b1 4.8 vs. 25.1 \u00b1 5.2, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) at 4 weeks compared with placebo. FMT via rectal enema demonstrated better IBS-SSS (168.7 \u00b1 101.9 vs. 269.3 \u00b1 69.5, <jats:italic>p<\/jats:italic> = 0.004), clinical response (73.3 vs. 26.7%, <jats:italic>p<\/jats:italic> = 0.011), and quality of life (30.2 \u00b1 5.0 vs. 21.0 \u00b1 7.4, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) than placebo. Clinical response and quality of life between encapsulated FMT and FMT via rectal enema were not different. No serious adverse event was observed. Minor adverse events such as bloating and diarrhea were not different between all groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Higher clinical response and quality of life were demonstrated in both FMT groups than placebo. Either encapsulated FMT or FMT via rectal enema was safe and could provide favorable outcomes for IBS patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical trial registration<\/jats:title><jats:p><jats:ext-link>https:\/\/clinicaltrials.gov\/study\/NCT06201182<\/jats:ext-link>, Identifier: NCT06201182.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1648944","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:31:55Z","timestamp":1758605515000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of encapsulated fecal microbiota transplantation and FMT via rectal enema for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial (CAP-ENEMA FMT Trial)"],"prefix":"10.3389","volume":"12","author":[{"given":"Natsuda","family":"Aumpan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soonthorn","family":"Chonprasertsuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bubpha","family":"Pornthisarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sith","family":"Siramolpiwat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patommatat","family":"Bhanthumkomol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navapan","family":"Issariyakulkarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pornpen","family":"Gamnarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phubordee","family":"Bongkotvirawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arti","family":"Wongcha-um","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varocha","family":"Mahachai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratha-korn","family":"Vilaichone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1136\/gutjnl-2015-311240","article-title":"The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review","volume":"66","author":"Sperber","year":"2017","journal-title":"Gut."},{"key":"B3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","article-title":"Pathophysiology of irritable bowel syndrome","volume":"1","author":"Holtmann","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.028","article-title":"The intestinal microenvironment and functional gastrointestinal disorders","author":"Barbara","year":"2016","journal-title":"Gastroenterology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3748\/wjg.v28.i4.412","article-title":"Gut bless you: The microbiota-gut-brain axis in irritable bowel syndrome","volume":"28","author":"Hillestad","year":"2022","journal-title":"World J Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1136\/gutjnl-2012-302167","article-title":"Intestinal microbiota in functional bowel disorders: a Rome foundation report","volume":"62","author":"Simren","year":"2013","journal-title":"Gut."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","article-title":"British Society of Gastroenterology guidelines on the management of irritable bowel syndrome","volume":"70","author":"Vasant","year":"2021","journal-title":"Gut."},{"key":"B8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal infusion of donor feces for recurrent Clostridium difficile","volume":"368","author":"van Nood","year":"2013","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/gutjnl-2016-313017","article-title":"European consensus conference on faecal microbiota transplantation in clinical practice","volume":"66","author":"Cammarota","year":"2017","journal-title":"Gut."},{"key":"B10","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1136\/gutjnl-2019-319630","article-title":"Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study","volume":"69","author":"El-Salhy","year":"2020","journal-title":"Gut."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.07.013","article-title":"Fecal microbiota transplantation reduces symptoms in some patients with irritable bowel syndrome with predominant abdominal bloating: short- and long-term results from a placebo-controlled randomized trial","author":"Holvoet","year":"2021","journal-title":"Gastroenterology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(17)30338-2","article-title":"Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial","volume":"3","author":"Johnsen","year":"2018","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1136\/gutjnl-2018-316434","article-title":"Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study","volume":"67","author":"Halkj\u00e6r","year":"2018","journal-title":"Gut."},{"key":"B14","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S2468-1253(19)30198-0","article-title":"Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial","volume":"4","author":"Aroniadis","year":"2019","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/gutjnl-2019-319407","article-title":"Scientific frontiers in faecal microbiota transplantation: joint document of Asia-Pacific Association of Gastroenterology (APAGE) and Asia-Pacific Society for Digestive Endoscopy (APSDE)","volume":"69","author":"Ng","year":"2020","journal-title":"Gut."},{"key":"B16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.5946\/ce.2019.009","article-title":"Fecal microbiota transplantation: an update on clinical practice","volume":"52","author":"Kim","year":"2019","journal-title":"Clin Endosc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/apt.17703","article-title":"Randomised clinical trial: Faecal microbiota transplantation for irritable bowel syndrome with diarrhoea","volume":"58","author":"Yau","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12866-021-02094-5","article-title":"Full-length 16S rRNA gene amplicon analysis of human gut microbiota using MinION nanopore sequencing confers species-level resolution","volume":"21","author":"Matsuo","year":"2021","journal-title":"BMC Microbiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41592-022-01520-4","article-title":"Emu: species-level microbial community profiling of full-length 16S rRNA Oxford Nanopore sequencing data","volume":"19","author":"Curry","year":"2022","journal-title":"Nat Methods."},{"key":"B20","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis","year":"1997","journal-title":"Aliment Pharmacol Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2020067","DOI":"10.1080\/19490976.2021.2020067","article-title":"Effect of antibiotic pretreatment on bacterial engraftment after Fecal Microbiota Transplant (FMT) in IBS-D","volume":"14","author":"Singh","year":"2022","journal-title":"Gut Microbes."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e00034","DOI":"10.14309\/ctg.0000000000000034","article-title":"The effect of allogenic versus autologous fecal microbiota transfer on symptoms, visceral perception and fecal and mucosal microbiota in irritable bowel syndrome: a randomized controlled study","volume":"10","author":"Holster","year":"2019","journal-title":"Clin Transl Gastroenterol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1111\/apt.15740","article-title":"Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome","volume":"51","author":"Lahtinen","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12876-022-02408-5","article-title":"Fecal microbiota transplantation in the treatment of irritable bowel syndrome: a single-center prospective study in Japan","volume":"22","author":"Hamazaki","year":"2022","journal-title":"BMC Gastroenterol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fcimb.2019.00002","article-title":"The super-donor phenomenon in fecal microbiota transplantation","volume":"9","author":"Wilson","year":"2019","journal-title":"Front Cell Infect Microbiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ajg.2013.59","article-title":"Fecal microbiota transplantation for Clostridium difficile infection: systematic review and meta-analysis","volume":"108","author":"Kassam","year":"2013","journal-title":"Am J Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s12876-023-02979-x","article-title":"Colonic distribution of FMT by different enema procedures compared to colonoscopy - proof of concept study using contrast fluid","volume":"23","author":"Skjevling","year":"2023","journal-title":"BMC Gastroenterol."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2018.01.003","article-title":"Strain tracking reveals the determinants of bacterial engraftment in the human gut following fecal microbiota transplantation","author":"Smillie","year":"2018","journal-title":"Cell Host Microbe"},{"key":"B29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.5056\/jnm22093","article-title":"The role of short chain fatty acids in irritable bowel syndrome","volume":"28","author":"Jiang","year":"2022","journal-title":"J Neurogastroenterol Motil."},{"key":"B30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000471919","article-title":"Bifidobacterium-rich fecal donor may be a positive predictor for successful fecal microbiota transplantation in patients with irritable bowel syndrome","volume":"96","author":"Mizuno","year":"2017","journal-title":"Digestion."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.05.003","article-title":"Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome","author":"Pinto-Sanchez","year":"2017","journal-title":"Gastroenterology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1053\/j.gastro.2004.11.050","article-title":"Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles","volume":"128","author":"O'Mahony","year":"2005","journal-title":"Gastroenterology."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1053\/j.gastro.2011.07.043","article-title":"Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome","volume":"141","author":"Rajilic-Stojanovic","year":"2011","journal-title":"Gastroenterology."},{"key":"B34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1186\/s12866-021-02380-2","article-title":"Involvement of mucosal flora and enterochromaffin cells of the caecum and descending colon in diarrhoea-predominant irritable bowel syndrome","volume":"21","author":"Yang","year":"2021","journal-title":"BMC Microbiol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.001","article-title":"Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial","author":"Moayyedi","year":"2015","journal-title":"Gastroenterology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/S0140-6736(17)30182-4","article-title":"Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial","volume":"389","author":"Paramsothy","year":"2017","journal-title":"Lancet."},{"key":"B37","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2019.03.049","article-title":"Gut microbiota in patients with irritable bowel syndrome-a systematic review","volume":"157","author":"Pittayanon","year":"2019","journal-title":"Gastroenterology."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1648944\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:31:55Z","timestamp":1758605515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1648944\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":37,"alternative-id":["10.3389\/fmed.2025.1648944"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1648944","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"article-number":"1648944"}}